An Interaction Study With Digoxin and AZD1305

AstraZeneca18 enrolled

Overview

The primary purpose of this study is to learn more about how digoxin is handled by the body, i.e. absorption, distribution, metabolism and excretion, when administered alone and in combination with AZD1305. Secondary purposes are to learn more about how AZD1305 is handled by the body when administered alone and in combination with digoxin and to learn more about how AZD1305 and digoxin administered alone and in combination affect the body.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Atrial Fibrillation

Interventions

AZD1305DRUG

Extended Release tablet, repeated administration

DigoxinDRUG

Tablet, repeated administration

Eligibility

Sex: MALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * A body mass index (BMI=weight/height2) of 19 to 30 kg/m2 Exclusion Criteria: * Potassium outside normal reference values * ECG findings outside normal range

Locations (1)

Research Site

Gothenburg, Sweden

Outcomes

Primary Outcomes

Pharmacokinetic variables

Time frame: During all dosing visits

Secondary Outcomes

Adverse event, vital signs, ECG, physical examination and laboratory variables.

Time frame: During the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.